Drug Trial Radar · NCT05573100
The Study of CU06-1004 in Patients With Diabetic Macular Edema (DME)
Last checked: Nov 19, 2026Latest source record: May 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Dec 21, 2022
Primary completion
May 31, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Curacle Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Théa Open Innovation, France
- First posted
- Oct 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU06-1004 orally administered once daily for 12 weeks. The study will have a 1:1:1 randomization (CU06-1004 100mg: CU06-1004 200mg: CU06-1004 300mg).
Conditions
- Diabetic Macular Edema
Interventions
CU06-1004Drug
CU06-1004 per capsule for oral administration. CU06-1004 is a white off powder at room temperature. The CU06-1004 100 mg soft gelatin capsules consist of a solution-based fill.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change of central subfield thickness (CST)Time frame: Baseline and 12 weeks
- To determine the optimal dosesTime frame: 12 weeks
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
Rand Eye Institute
Deerfield Beach, Florida
Elman Retina Group
Baltimore, Maryland
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
New England Retina Consultants
Springfield, Massachusetts
Mid Atlantic Retina
Bethlehem, Pennsylvania
Austin Research Center for Retina
Austin, Texas
Retina consultant of Texas
Bellaire, Texas
Valley Retina Institute
McAllen, Texas
Wagner Macula and Retina Center
Norfolk, Virginia
Emanuelli Research & Development Center
Arecibo, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.